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Abstract The ability of protein tyrosine kinases to phosphor- 
ylate a synthetic peptide was inhibited 51% by peroxynitrite- 
mediated nitration of tyrosine. Exposure of endothelial cells to 
peroxynitrite decreased the intensity of tyrosine phosphorylated 
proteins and increased the intensity of nitrotyrosine-containing 
proteins. Peroxynitrite-modified BSA was degraded by human 
red blood cell lysates. However, human plasma in a concentra- 
tion-, time-, and temperature-dependent manner, removed the 
protein nitrotyrosine epitope. These results suggest that tyrosine 
nitration interferes with phosphorylation and targets proteins for 
degradation. Specific enzymatic process(es) for removing nitro- 
tyrosine may be present in vivo. 
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1. Introduction 
Peroxynitrite, the product of the near diffusion limited re- 
action between nitric oxide (‘NO) and superoxide, induces a 
series of oxidative protein modifications [l-5]. The nitration of 
the ortho position of tyrosine residues in proteins by peroxy- 
nitrite has been considered a specific marker for the detection 
of peroxynitrite in vivo [1,5]. As such, using a variety of 
methods for detecting nitrotyrosine, several reports have 
shown that nitrotyrosine is associated with the induction of 
oxidative stress in human and animal models of disease [6-191. 
Although the above body of published data has suggested that 
nitrotyrosine represents a protein modification specific for 
peroxynitrite formation in vivo, the possible role of tyrosine 
nitration in cellular function has not been fully explored. For 
example, tyrosine phosphorylation is an important regulator 
of signal transduction in cells and nitrotyrosine formation 
may interfere with normal signal transduction pathways. Pre- 
liminary data by Kong et al. showed that peroxynitrite- 
mediated nitration of a single tyrosine residue in the cell cycle 
kinase cdc2 prevents tryrosine phosphorylation [20]. Data pre- 
sented here suggests that nitrotyrosine formation is responsi- 
ble for the inhibition of tyrosine phosphorylation in endothe- 
lial cells exposed to low levels of peroxynitrite. 
Nitration of tyrosine residues has been utilized as a protein 
modification to study the role of specific tyrosine residues in 
the function of proteins. Chemically induced tyrosine nitra- 
tion has been shown to inactivate nearly 140 mammalian pro- 
teins whose activity is dependent on tyrosine residues [21]. 
Thus far peroxynitrite-mediated nitration of tyrosine residues 
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has been shown to inactivate the mitochondrial Mn superox- 
ide dismutase [l], the lipid aggregatory activity of surfactant 
protein A [22], and glutamine synthetase activity [23]. In fixed 
and freshly prepared tissues nitrotyrosine is stable and can be 
easily detected by a variety of techniques including specific 
affinity-purified polyclonal and monoclonal antibodies, amino 
acid analysis, HPLC analysis and GUMS. However, we have 
observed that the levels of nitrotyrosine in non-fixed tissue 
and plasma samples stored even at -80°C decline over time. 
Therefore, we examined the possibility that proteolytic and 
other degradative pathways may exist in these samples that 
were responsible for the loss of nitrotyrosine. 
2. Materials and methods 
2.1. Cell culture, methods for exposing cells to ‘NO, and ONOO- and 
Western blof analysis 
Starter cultures of bovine pulmonary artery endothelial cells 
(BPAEC) were originally a gift of Dr. E.J. Macarack (Connective 
Tissue Research Institute, University of Pennsylvania). The cells 
were subcultured as necessary on 35 cm* plastic tissue culture plates. 
Studies were performed at l-3 days postconfluence and at passage 3- 
6. For experimental use, confluent monolayers of BPAEC (0.8- 
1.0 X lo6 cells per well of a 24 cm* plate) were washed three times 
with Earle’s balanced salt solution (supplemented with 2.5 mM 
HEPES and 10 mM glucose) and equilibrated at 37°C. The nitric 
oxide donor utilized in these studies was spermine-NO (Cayman 
Chemical Co., Ann Arbor, MI), ‘NO was released at 2 pmol/min. 
For exposure to ONOO-, 3-morpholinosydnonimine (SIN-l) was uti- 
lized as described previously [24], to release ONOO- at 2 lrmol/min 
for 2 h. Protein concentration in cell lysates prepared after sonication 
of harvested cells (10 s x 3 times at 75 W) was determined by the Bio- 
Rad protein assay kit. Endothelial cell lysates were separated using 
12% SDS-PAGE electrophoresis and transferred overnight to nitro- 
cellulose. After blocking with 5% dry milk in Tris-buffered saline 
(TBS), the nitrocellulose was exposed to the anti-nitrotyrosine anti- 
body at a concentration of 0.5 @ml or to monoclonal anti-phospho- 
tyrosine antibody (Oncogene Science) in 0.5% dry milk in TBS for 1 
h. The antibody binding was visualized by luminol-enhanced chemi- 
luminescence (Amersham, Arlington Heights, IL). 
2.2. Phosphorylation assay 
The activity of the tyrosine kinases c-src and v-abl in phosphorylat- 
ing nitrated and non-nitrated substrate was assayed using a protein 
tyrosine kinase assay as per manufacturer’s instructions (Oncogene 
Science). Briefly, a modified gastrin analog (Raytide), containing a 
single tyrosyl residue, is used as a substrate. 0.1 units of enzyme (1 
unit of enzyme catalyzes the incorporation of 1 pmol of phosphate per 
min from ATP onto tyrosvl residues) are reacted with 4 nmol of 
Raytide in 50 mM HEPES- pH 7.5 containing 0.1 mM EDTA and 
0.015% Brii 35. The reaction is started bv adding 0.05 mM ATP 
containing -10 mM MgC12 and 2 ltCi of [y-32P]ATP. The reaction 
mixture was incubated for 30 min at 30°C. Reaction was stopped 
by adding 10% phosphoric acid and then the reaction mixture was 
applied to p81 Whatman paper. The papers were washed with 0.5% 
phosphoric acid and acetone, dried, and quantited by liguid scintilla- 
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tion counting. To measure the phosphorylation of nitrated substrate, 
the Raytide was reacted with a lo-fold excess of chemically synthe- 
sized peroxynitrite. 
2.3. Protein degradation assays 
Fatty acid-free bovine serum albumin was labeled with i4C by re- 
ductive methylation as described previously [25,26]. The protein was 
reacted with peroxynitrite in 100 mM potassium phosphate, 0.9% 
NaCl buffer that contained 100 uM of the metal chelator diethylene- 
triaminepentaacetic acid (DTPA), pH 7.4 to give a molar ratio of 
protein to peroxynitrite of 1: 10. The yield of nitration was determined 
by measuring the absorbance at pH 11.5 (&4ssnrrr = 4400 M-’ cm-‘). 
Fresh plasma and red blood cells were collected from adult volun- 
teers. The plasma was centrifuged at 10000 xg and diluted with 100 
mM potassium phosphate buffer, pH 7.4, to obtain aliquots with I mg 
protein/ml. Red blood cell lysates were prepared as described pre- 
viously [25]. For proteolytic degradation 5 mg /ml of red blood cell 
lysate was incubated with 0.3 mglml of labelled nitrated protein and 
the proteolytic degradation was measured as described previously 
[25,26]. 
2.4. Nitrotyrosine degradation assay 
A solid-phase immunoradiochemical assay was used to measure 
nitrotyrosine degradation. Tissue proteins, plasma and peroxynitrite- 
modified BSA were immobilized onto nitrocellulose using the 96well 
Bio-Dot microfiltration unit (BioRad, Hercules, CA). This assay was 
developed previously and the binding characteristics of the antibody 
established [27]. Eight to twelve different concentrations of the 
peroxynitrite-modified BSA standard were loaded in duplicate for 
each blot. Four to eight concentration-dependent dilutions of the 
samples were loaded in 400 ul TBS. After blocking with 5% dry 
milk the nitrocellulose was incubated with the anti-nitrotyrosine anti- 
body for 15 h followed by a 3 h incubation in solution containing a 
donkey anti-rabbit 12”I-labeled IgG (0.1-0.2 mCi/ml). The blot was 
extensively washed in Tween-TBS and dried. The radioactivity of each 
sample was measured directly by beta scanning using an Ambis 400 
imaging detector. The net counts of radioactivity (corrected for back- 
ground counts from a sample blank) were obtained using the Ambis 
image analysis software ~4.1 and then plotted on a semi-logarithmic 
plot. The binding of the antibody was saturable and dependent on the 
concentration of the antibody and antigen. At antibody concentration 
of 2 ug/ml the binding of nitrotyrosine increased linearly with increas- 
ing antigen concentration up to 1 ug of nitrotyrosine. The linear 
portion of the antibody binding curve to immobilized antigen was 
utilized to study the effects of nitrotyrosine degradation. 
3. Results and discussion 
The hypothesis that nitrotyrosine formation in proteins in- 
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Cold BSA PhSIM RBC Lysates 
Fig. 1. Effects of peroxynitrite in tyrosine phosphorylation in bovine 
pulmonary artery endothelial cells. Equal amounts of endothelial 
cell lysate protein (20 ug) were separated on a 12% SDS-PAGE gel, 
transferred to nitrocellulose and probed with a monoclonal anti- 
phosphotyrosine antibody (A) and with an affinity-purified polyclo- 
nal anti-nitrotyrosine antibody (B). The data is a representative ana- 
lysis of a duplicate experiment with the same tyrosine nitrated and 
phosphorylated bands found in the second analysis. Lanes: 1,6, con- 
trol; 2,5, SIN-l treated; 3,4, spermine-NO treated. 
terferes with tyrosine phosphorylation was tested: (1) In vitro 
using a synthetic commercially available peptide that is a 
modified gastrin analog with one tyrosyl residue at the car- 
boxy1 terminal. This peptide is a substrate for the tyrosine 
kinases v-abl (~43”~“~‘) and c-src (p60c-src). These tyrosine 
kinases are known to phosphorylate a number of cellular 
proteins after stimulation with growth factors and cytokines 
[28]. (2) In endothelial cell lysates after exposure of cells to 
peroxynitrite. 
The phosphorylation of the 2.2 kDa synthetic peptide by 
purified tyrosine kinases (~43”~“” and p60c--srr) was inhibited 
by 51% (2037? 190 vs. 1007+ 152 cpm, IZ = 3) when the pep- 
tide was first reacted with ONOO- to form nitrotyrosine. The 
peptide was reacted with peroxynitrite at a ratio of 1 to 10, 
which has previously been shown to yield 100% nitration of 
tyrosine residues [l]. It is important to note that the phos- 
phorylation reaction is performed in a large excess of sub- 
strate (4 nmol of peptide to 0.1 units of enzyme). Therefore, 
this assay measures the effect of nitration on the rate of phos- 
phorylation of the substrate. This reduced phosphorylation 





Fig. 2. (A) SDS-PAGE analysis of i4C-labelled fatty acid-free BSA reacted with peroxynitrite at ratio of 1: 10 (protein to ONOO-) and incu- 
bated at 37°C for 60 min with cold BSA, human plasma and RBC lysates. Gels were subjected to scanning by Ambis 4000 and the intensity of 
the bands measured. 100% was set as the intensity of the band from the sample incubated with cold BSA. (B) Nitrated BSA was mixed with 
different concentrations of human plasma and blotted without incubation onto nitrocellulose. 
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Fig. 3. (A) Concentration-dependent loss of antibody binding of nitrated BSA. Various concentrations of nitrated BSA were incubated with dif- 
ferent protein concentrations of human plasma to give the following ratios; (w) 1 :0, (0) 1:0.005, (A) 1:0.05, (v) 1: 0.5 and (0) 1:.5 for 30 
min at 37°C. (B) Same experiment as in A but the incubation was performed at 4°C. (C) Nitrated BSA was incubated with human plasma at 
1: 1 protein ratio and incubated for various time at 37°C. The control (m) is without plasma at 30 min and (0) indicates time zero, (0) 5 min, 
(A) 10 min, (v) 15 min and (0) 30 min. (D) Same experiment as in C but the incubation was performed at 4°C. 
showing that IV-acetylimidazole-mediated acetylation of the 
phenolic hydroxyl group in tyrosine is reduced when the ortho 
position of tyrosine is nitrated [29]. In addition, the same 
work showed that the phosphorylation of tyrosine is signifi- 
cantly affected by the pK, of the the phenolic hydroxyl group. 
The normal pK, of the hydroxyl group is 10.07 and substitu- 
tions that shifted toward lower pK, values decreased the rate 
of phosphorylation [22]. Nitration of the ortho position of 
tyrosine shifts the pK, of the aromatic hydroxyl group to 
7.5 which may provide the mechanism for the significantly 
reduced rate of phosphorylation. 
Confluent monolayers of BPAEC were exposed to either 
peroxynitrite or nitric oxide at 10 pM/min for 2 h. After ex- 
posure, cell lysates were prepared in the presence of protein 
phosphatase inhibitors (20 PM orthovanadate) and protease 
inhibitors (5 mM PMSF, 0.1 pg/ml aprotinin and leupeptin), 
and the cell lysate proteins were separated by 12% SDS- 
PAGE under reducing conditions (Fig. 1). Western blot anal- 
ysis of endothelial cell lysates using monoclonal anti-phospho- 
tyrosine antibodies revealed approx. 7 phosphorylated bands 
ranging from 50 to 150 kDa. The protein bands located ap- 
proximately at 143, 100, 90, 80 and 70 kDa showed the great- 
est binding to anti-phosphotyrosine antibodies. The antibody 
binding of these bands was markedly reduced following ex- 
posure to ONOO- but to a much lesser degree following 
nitric oxide exposure (Fig. 1A). Analysis of endothelial cell 
lysates using an affinity-purified polyclonal anti-nitrotyrosine 
antibody demonstrated increased nitration of some of the 
protein bands which showed reduced binding with the phos- 
photyrosine antibody after ONOO- exposure (indicated by 
the arrows in Fig. 1B). The presence of nitrated proteins with- 
in control lysates is not surprising as nitrotyrosine has been 
previously detected in both control cell lysates and in normal 
human plasma [19]. These results suggest that ONOO- re- 
duced tyrosine phosphorylation by nitrating tyrosine resi- 
due(s). Published data has shown that the activity of protein 
kinases and protein tyrosine phosphatases is reduced by ex- 
posure to oxidants, via oxidation of critical cysteine residues 
[30,31]. However, to establish the involvement of such a mech- 
anism in this system requires further experimentation. 
Davies and co-workers have provided extensive evidence 
that oxidative modification of proteins increases their suscept- 
ibility to proteolytic degradation [25,26]. Removal of modified 
proteins and increased protein turnover can be considered 
another line of defense against oxidative stress. Therefore, 
we tested if ONOO--reacted BSA was cleaved more efficiently 
than unreacted BSA by proteolytic enzymes present in human 
red blood cell lysates. Proteolytic degradation was measured 
by the percentage of 14C that was acid soluble post incuba- 
tion. After incubation of control BSA with red blood cell 
lysates 0.65 f 0.18% (n = 4) of counts were acid soluble. 
ONOO--modified BSA was degraded more rapidly than the 
control, 4.95 _+ 0.90% (n = 4) of counts being acid soluble. 
This increased degradation is confirmed by Fig. 2A, which 
shows a 50% reduction in labelled nitrated BSA post incuba- 
tion with red blood cell lysates. Although peroxynitrite can 
modify other residues in BSA [5] under these experimental 
conditions, it appears that tyrosine nitration may also be a 
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signal for proteolytic degradation. Recently, Bartlett et al. 
showed that tyrosine nitration increases proteolytic degrada- 
tion of glutamine synthetase [23]. 
Previously, while developing a solid-phase immunoassay for 
nitrotyrosine quantification in proteins, we discovered that 
human plasma and rat tissue homogenates from brain, lung 
and liver, had the ability to remove the nitrotyrosine epitope. 
Upon examination of the activity within plasma, it did not 
appear to be due to proteolytic degradation. SDS-PAGE 
analysis of peroxynitrite-modified fatty acid free BSA after 
incubation with plasma did not reveal loss of the 14C label 
(Fig. 2A). For the solid-phase immunoassay, various dilutions 
of BSA that contained a known amount of nitrotyrosine were 
placed on nitrocellulose paper. After proper blocking, anti- 
nitrotyrosine antibody is allowed to react and the amount 
of the primary antibody binding was quantified by radioactiv- 
ity counting on an Ambis scanner after addition of ““I-la- 
beled secondary antibody. As shown in Figs. 2 and 3, plots 
of log of concentration versus the net counts showed a linear 
relationship for concentrations of nitrotyrosine ranging from 
5 to 100 ng. Plasma appears to remove nitrotyrosine in a time, 
concentration- and temperature-dependent manner (Fig. 3). 
This action resulted in the detection of less nitrotyrosine, as 
evident by the parallel shift to the right in the plots of log of 
concentration versus the net counts. Plasma added to nitro- 
tyrosine-containing BSA immediately prior to addition of the 
primary antibody did not interfere with the ability of the anti- 
body to detect nitrotyrosine (Fig. 2B). The loss of nitrotyro- 
sine after incubation with plasma was confirmed by amino 
acid analysis. The nitrotyrosine content of ONOO--modified 
fatty acid free BSA was 0.15 f 0.03 mol% (n = 3) whereas 
after treatment with human plasma, for 1 h at 37°C content 
was reduced to 0.09f0.01 mol% (n = 3). These observations 
raised an interesting question. How can we detect nitrated 
proteins in plasma if plasma degrades nitrotyrosine-containing 
proteins? We repeated the same experiment as in Fig. 3 (37YZ 
and 30 min incubation), but instead of fresh plasma we used 
plasma that was reacted with ONOO-. The plasma reacted 
first with ONOO- did not have nitrotyrosine-degrading activ- 
ity, suggesting that the nitrotyrosine-degrading activity was 
inhibited by peroxynitrite. These results indicate that plasma 
and tissues can degrade peroxynitrite-modified proteins. 
Therefore, caution must be taken during sample analysis for 
nitrotyrosine. Inclusion of protease inhibitors and decrease 
time of storage may be necessary for succesful detection. 
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